CAM
IBB icon

Capstone Asset Management’s iShares Biotechnology ETF IBB Stock Holding History

Capstone Asset Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2,490
Closed -$213K – 1654
2014
Q2 		$213K Buy
+2,490
New +$196K 0.01% 1557

Other funds holding IBB

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
CM
Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Capstone Asset Management's IBB Position: Q3 2014 in Review

Capstone Asset Management sold out of iShares Biotechnology ETF (IBB) in Q3 2014, closing a stake of 2,490 shares — an estimated $213K sold.

Capstone Asset Management first reported a position in IBB in Q2 2014 and held it in 1 quarter. The position peaked at $213K in Q2 2014. 318 funds tracked by Wall St. Rank hold IBB as of Q3 2014.

  • Capstone Asset Management reported no remaining iShares Biotechnology ETF position as of Q3 2014 after selling out during the quarter.
  • Capstone Asset Management sold 2,490 iShares Biotechnology ETF shares in Q3 2014, an estimated $213K.
  • Capstone Asset Management first reported a position in iShares Biotechnology ETF in Q2 2014 and held it in 1 quarter.
  • Capstone Asset Management's iShares Biotechnology ETF position peaked at $213K in Q2 2014.
  • 318 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2014.

Based on Capstone Asset Management's 13F filing for Q3 2014, filed 14 Oct 2014.